

Teva Canada Limited | Media Statement | December 18, 2024

^{T/C}TEVA-CLOBAZAM 10 mg TABLETS SUPPLY

Please find below a copy of an updated Media Statement as well as some additional information provided by Teva Canada.

Teva Canada started experiencing a backorder in May 2024 and posted on Health Canada's Drug Shortages Website with a current return to market in April 2025. (<https://www.drugshortagescanada.ca/shortage/229230>)

Teva does not have any remaining stock at our distribution centre in Canada; however there maybe limited quantities of stock remaining at some pharmacies.

Teva Canada is committed to providing consistent access to medications for all patients who rely on our medications. We recognize the anxiety these shortages can create and do our best to work with patients to mitigate their concerns. In exceptional circumstances, where a patient has experienced an issue with the non-Teva product, they could contact Teva Canada Customer Service (customer.service@tevacanada.com). We would attempt to find a pharmacy that may have a small amount of remaining inventory.

Teva Canada appreciates your efforts to provide this resource to your patients but requests that all media inquiries related to Teva Canada be directed to our PR firm, Relevants Inc. (media@relevants.ca)

Teva Canada Limited | Media Statement | December 17, 2024

^{T/C}TEVA-CLOBAZAM 10 mg TABLETS SUPPLY

While Teva Canada is experiencing a temporary backorder of **^{T/C}TEVA-CLOBAZAM (clobazam) 10 mg Tablets**, we would like to remind patients requiring treatment with this medication that there is an alternative brand of 10 mg clobazam tablets available in the Canadian market manufactured by Apotex.

Patients with questions regarding their medication are advised to speak to their healthcare professional to discuss available treatment options. As updates become available on the backorder situation, they can be found on the Drug Shortages Canada website (www.drugshortagescanada.ca) or on the Teva Canada website (www.tevacanada.com).

Teva Canada continues to work diligently to expedite our return to the market recognizing the importance of this medicine to patients living with epilepsy.